Acrivon Therapeutics, Inc.

Develops precision cancer therapies by matching patients to drugs using its proteomics platform.

ACRV | US

Overview

Corporate Details

ISIN(s):: US0048901096
LEI:
Country:: United States of America
Address:: 480 ARSENAL WAY, SUITE 100, 2472 WATERTOWN
Website:: https://acrivon.com/
Sector:: Mining and quarrying
Industry:: Mining of non-ferrous metal ores

Description

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology. The company leverages its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to develop targeted cancer therapies. The AP3 platform utilizes phosphoproteomics to analyze the biologic drivers of a patient's cancer, enabling the creation of predictive 'OncoSignature' tests. This method is designed to match drug candidates with patients whose tumors are most likely to respond, aiming to improve therapeutic outcomes beyond what is achievable with genomics. Acrivon's pipeline is led by ACR-368, a selective kinase inhibitor in Phase 2 clinical trials for various solid tumors. The company also advances its internally developed programs and seeks strategic partnerships to apply its AP3 platform to co-develop predictive tests for external drug candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Acrivon Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Acrivon Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Acrivon Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
SYNAIRGEN PLC Developing inhaled interferon beta treatments for severe viral lung infections in hospitalized patients.	United Kingdom	SNG
Synerga Fund Spolka Akcyjna Commercializes medical therapies globally using industrial property and copyrights for clinical use.	Poland	SNG
Synergie SE Offers global HR services, including temporary/permanent recruitment and workforce solutions.	France	SDG
SyntekaBio,Inc. AI drug discovery platform accelerating R&D with supercomputing, SaaS, and pre-made candidates.	South Korea	226330
Targetspot S.A. AdTech firm for digital audio monetization, connecting brands to publishers' audiences.	Belgium	ALTGS
TechnoPro Holdings, Inc. Technology staffing and services group providing engineers and solutions for R&D and development.	Japan	6028
TechTarget, Inc. Provides purchase intent-driven marketing and sales services for B2B tech vendors.	United States of America	TTGT
Tenaya Therapeutics, Inc. Developing gene therapy, cellular regeneration & precision medicine for heart disease.	United States of America	TNYA
Terns Pharmaceuticals, Inc. Clinical-stage biopharma developing small-molecule drugs for oncology & metabolic diseases.	United States of America	TERN
Thalassa Holdings Ltd. A holding company active in property rentals and marine seismic & defense R&D.	Virgin Islands (British)	THAL